-
Cocrystal Pharma NASDAQ:COCP Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Location: 19805 N Creek Pkwy, Washington, 98011-8251, US | Website: www.cocrystalpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.441M
Cash
18.14M
Avg Qtr Burn
-3.552M
Short % of Float
0.84%
Insider Ownership
30.03%
Institutional Own.
6.68%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral CC-42344 Details Influenza | Phase 2a Data readout | |
CC-31244 (Pan-genotypic NS5B NNI) Details Hepatitis C | Phase 2a Update | |
CDI-988 Details COVID-19, Norovirus | Phase 1 Data readout | |
Inhaled CC-42344 Details Influenza | Phase 1 Initiation | |
CDI-45205 Details COVID-19 | IND Submission |